For patients in different clinical subgroups (age, gender, hemoglobin index, tumor location, pathological gradeand clinical stage), K-M survival analysis also indicated that the survival of the patients with higher STEAP3 expression was significantly shorter regardless of the subgroup the patients belonged to (Fig. 2E). This evidence concerns the gene STEAP3 and neoplasm.